Hyperfine Sees Q3 Sales $3.400M vs $3.507M Est Becton Dickinson Narrows FY2025 Sales Guidance from $21.800B-$21.900B to $21.800B vs $21.863B Est Orchid Island Capital Announces Estimated Q3 2025 ...
Suggested remit: To appraise the clinical and cost effectiveness of talquetamab within its marketing authorisation for treating relapsed or refractory multiple myeloma after 3 treatments.
Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: Early Value Assessment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback